GLP-1 Research Cycle Summary — May 29, 2026

This research cycle tracked the most significant commercial, clinical, and medical device developments in the GLP-1 and obesity space as of May 29, 2026. The dominant themes of this cycle highlight a major shift in commercial market access, the emergence of a powerful new public pipeline challenger, and a technological leap in metabolic biowearables.

1. CVS Caremark Erases Novo's Formulary Advantage

In a major commercial shift, pharmacy benefit manager (PBM) CVS Caremark announced that it will end its exclusive preference for Novo Nordisk’s Wegovy. Starting June 1, 2026, CVS Caremark will place Eli Lilly’s newly approved oral weight-loss pill, Foundayo™ (orforglipron), on its commercial formularies. It will also restore coverage for Lilly’s injectable Zepbound® (tirzepatide) as a preferred option starting October 1, 2026.

• Market Access Parity: With this move, Eli Lilly's obesity portfolio is now covered by all three of the largest PBMs in the United States (CVS Caremark, Express Scripts, and OptumRx).
• Catalyst for Foundayo: This preferred status is expected to significantly accelerate the commercial launch of Foundayo, which had experienced a slower initial prescription trajectory compared to Novo's oral Wegovy pill.
• For more details, see: CVS Caremark Restores Zepbound Coverage and Adds Foundayo Pill, Erasing Novo's Formulary Advantage

2. Kailera's Triple-G Agonist KAI-4729 Emerges as a Potent Threat

Newly public competitor Kailera Therapeutics (NASDAQ: KLRA) reported stellar Phase 1 data for its "triple-G" agonist candidate, KAI-4729 (licensed from Chinese partner Hengrui Pharmaceuticals).

• 16% Weight Loss in 12 Weeks: Enrollees on an escalated dosing regimen lost an average of 16% of their body weight over 12 weeks. This early-stage trajectory outperforms Eli Lilly's leading triple-G agonist, retatrutide, which had not yet reached 10% weight loss at the 12-week mark in its clinical trials.
• Strong Capital Runway: Backed by its massive $625 million IPO, Kailera is fully funded into mid-2028 and is preparing to launch Phase 1 trials for KAI-4729 outside of China, while Hengrui advances the drug to Phase 2 in China.
• For more details, see: Kailera's Triple-G Agonist KAI-4729 Achieves 16% Weight Loss in Phase 1, Outperforming Early Benchmarks

3. Abbott Secures CE Mark for World's First Dual Glucose-Ketone Sensor

The continuous glucose monitoring (CGM) and medical device landscape achieved a major technological milestone on May 27, 2026, when Abbott Laboratories (NYSE: ABT) secured CE Mark approval for its Libre Duo and Libre Duo 10 Day systems.

• Continuous Ketone Monitoring: Libre Duo is the first-ever biowearable to continuously monitor both glucose and ketones in a single sensor, helping patients detect rising ketones early to prevent life-threatening diabetic ketoacidosis (DKA). Abbott expects U.S. FDA approval in the second half of 2026.
• Dexcom's Divergent Strategy: Dexcom is focusing its multi-analyte pipeline on glucose and potassium sensing to target chronic kidney disease rather than ketones. Dexcom also recently previewed its Dexcom G8 CGM sensor, which is 50% smaller than the G7 and features a 15-day wear time, with an expected launch in late 2027 or early 2028.
• For more details, see: Abbott Secures CE Mark for World's First Dual Glucose-Ketone Sensor, as Dexcom Previews Dexcom G8

4. The Limits and Risks of Super-Potency

As next-generation "triple-G" agonists (targeting GLP-1, GIP, and glucagon) like Eli Lilly's retatrutide and Kailera's KAI-4729 push the boundaries of weight loss toward bariatric surgery levels (up to 30% weight loss), clinical discussion is increasingly focusing on the risks of extreme potency.

• Cardiovascular & Muscle Safety: Super-potent multi-receptor agonists carry risks of persistent resting heart rate elevation, palpitations, and accelerated muscle/bone loss if rapid weight loss is not paired with structured resistance training and nutritional support.
• Eating Disorders: Clinicians are raising alarms regarding patients with active eating disorders (such as anorexia or bulimia) obtaining easy online telehealth access to these highly potent weight-loss agents.